Introduction: Who Should Seek Diagnostic Testing

If you develop certain symptoms after a medical procedure, an injury, or if you have an existing lung condition, your doctor may recommend testing for Mycobacterium abscessus, a bacterium found naturally in water, soil, and dust. This bacterium is part of a group called nontuberculous mycobacteria, which means it is distantly related to the bacteria that cause tuberculosis but is not the same.^[1]

People who should consider seeking diagnostic testing include those who develop symptoms after receiving medical care, particularly if they notice boils or pus-filled blisters on their skin, or experience fever, chills, or general feelings of illness. The infection can occur when contaminated equipment is used during surgery or other invasive procedures, or when the bacteria enter through an open wound.^[1]

Individuals with chronic lung diseases such as cystic fibrosis, bronchiectasis, asthma, or emphysema are at higher risk and should be especially vigilant about respiratory symptoms. If you have an underlying lung condition and develop a persistent cough (sometimes with blood), shortness of breath, fever, or fatigue, these signs warrant medical attention and diagnostic testing.^[1][2]

People with weakened immune systems, including those with HIV, cancer, or those taking immunosuppressive medications, should also seek diagnostic evaluation if they develop symptoms. Women with low body mass index and certain health conditions like chronic acid reflux, scoliosis, or specific heart valve problems may also be at increased risk for lung infections caused by this bacterium.^[17]

Classic Diagnostic Methods

The diagnosis of Mycobacterium abscessus infection begins with your doctor taking a sample from the area that appears to be infected. This process is essential because the bacterium needs to be identified in a laboratory before treatment can begin. The type of sample collected depends on where the infection is located in your body.^[1][13]

For skin and soft tissue infections, healthcare providers will take a sample from the infected area, which may involve collecting pus or tissue from a wound, abscess, or blister. If the infection is suspected to be in the lungs, doctors will need a sample of sputum, which is the mucus you cough up from your airways. In some cases, blood samples may also be collected, particularly if there is concern about the infection spreading throughout the body.^[1][12]

Laboratory Culture and Identification

Once the sample reaches the laboratory, it is placed in special growth media to allow any bacteria present to multiply. Because Mycobacterium abscessus is classified as a rapid-growing mycobacterium, it typically shows growth within three to seven days on laboratory plates, which is much faster than other mycobacteria like those that cause tuberculosis. However, even “rapid” growth still takes several days, so patients must wait for results.^[4][15]

Laboratories use both solid and liquid media to maximize the chances of detecting the bacterium. Solid media such as 7H10 and 7H11 are commonly recommended, while some laboratories also use Löwenstein-Jensen slants, which are considered highly sensitive for detecting mycobacteria. The use of both types of media increases the overall sensitivity of the diagnostic process.^[4][15]

For respiratory specimens, the samples are typically treated with special solutions to remove contaminating bacteria and other microorganisms that might interfere with mycobacterial growth. This treatment process, called decontamination, uses substances like N-Acetyl-L-cysteine and sodium hydroxide to ensure that only mycobacteria can grow in the culture.^[4][15]

Subspecies Identification

Identifying that a bacterium is Mycobacterium abscessus is only the first step. This organism is actually a complex that includes three distinct subspecies: Mycobacterium abscessus subspecies abscessus, Mycobacterium abscessus subspecies massiliense, and Mycobacterium abscessus subspecies bolletii. Knowing which subspecies is causing the infection is critically important because they respond differently to treatment.^[2][4]

Standard biochemical and physical characteristics alone cannot reliably distinguish between these subspecies, so molecular identification methods are necessary. These advanced techniques involve analyzing specific genes within the bacterium, such as the hsp65 or rpoB genes. This genetic testing helps doctors predict how the infection will respond to certain antibiotics, particularly macrolides like clarithromycin.^[4][15]

The subspecies abscessus and bolletii often have a gene called erm(41) that can make them resistant to macrolide antibiotics after initial exposure to these drugs. This resistance can develop during treatment, which is why testing for this gene is recommended. In contrast, subspecies massiliense typically lacks a functional erm gene, which means it is more likely to remain sensitive to macrolide antibiotics throughout treatment.^[4][11][15]

Drug Susceptibility Testing

After identifying the bacterium and its subspecies, the laboratory performs drug susceptibility testing to determine which antibiotics will be effective against the specific strain causing your infection. This testing is crucial because Mycobacterium abscessus is known for being resistant to many commonly used antibiotics, making it one of the most challenging infections to treat.^[2][7]

The laboratory tests various antibiotics to see which ones can inhibit the growth of the bacteria. Common antibiotics tested include clarithromycin, amikacin, cefoxitin, and imipenem. The results help your healthcare provider choose the most appropriate combination of drugs for your specific infection. Testing also helps identify whether your bacterial strain has inducible macrolide resistance, which can develop after several days of exposure to macrolide antibiotics.^[4][15]

Distinguishing from Other Conditions

One challenge in diagnosing Mycobacterium abscessus is that it can sometimes be confused with other bacteria. In laboratory cultures, particularly in liquid growth systems, the bacterium may initially be mistaken for Corynebacterium species, which are often described as diphtheroids. Additionally, it must be distinguished from other rapid-growing mycobacteria like Mycobacterium fortuitum and Mycobacterium chelonae, which require different treatment approaches.^[4][15]

Special biochemical tests help differentiate Mycobacterium abscessus from these related organisms. For example, unlike some other rapid-growing mycobacteria, Mycobacterium abscessus typically does not reduce nitrate and does not take up iron in specific laboratory tests. It also shows tolerance to certain chemicals in growth media, such as sodium chloride and picrate, which helps laboratory technicians identify it correctly.^[3][4]

Diagnostics for Clinical Trial Qualification

When patients are being considered for participation in clinical trials evaluating new treatments for Mycobacterium abscessus infection, they typically undergo additional, more detailed diagnostic testing. These tests serve as standard criteria to ensure that trial participants have confirmed infections and that researchers can accurately measure treatment responses across all study participants.^[9]

Clinical trial eligibility usually requires documented evidence of Mycobacterium abscessus infection through positive cultures from clinical specimens. For pulmonary infections, this typically means obtaining multiple sputum samples over a period of time to confirm that the infection is persistent and not just a one-time finding or contamination. Researchers need to distinguish between true infection and simple colonization, where the bacteria are present but not causing active disease.^[9][12]

Sputum Collection and Testing Standards

For lung infections, clinical trials often require specific protocols for collecting sputum samples. Patients may be asked to provide samples on multiple occasions, and these samples must be collected properly to ensure they represent material from deep in the lungs rather than just saliva. In some cases, if patients cannot produce sputum naturally, a procedure called sputum induction may be performed, where inhaled saline solution helps bring up lung secretions.^[12]

Trials typically monitor how quickly bacteria clear from sputum after treatment begins. Sputum samples are collected every one to two months after treatment initiation to assess whether the treatment is working. Research has shown that most patients who successfully respond to treatment achieve what is called culture conversion—meaning their sputum no longer grows the bacteria—within six months of starting therapy.^[12][16]

Radiologic Evaluation

Clinical trials for Mycobacterium abscessus often require chest imaging studies to document the extent and type of lung disease. Computed tomography (CT) scans provide detailed images that show whether the infection has created cavities in the lungs, areas of consolidation, or other structural changes. The presence of cavitary disease, where hollow spaces form in lung tissue, and the size of these cavities are important factors that researchers monitor throughout the trial.^[16]

The extent of disease visible on CT scans—such as the number of lung lobes involved—helps researchers categorize patients and predict treatment outcomes. Studies have found that more extensive disease at the start of treatment is associated with a lower likelihood of successful cure, so this information helps researchers understand whether new treatments work better for certain types of disease.^[16]

Molecular and Genetic Testing

Many clinical trials require molecular testing to identify not just the presence of Mycobacterium abscessus but also its specific subspecies and resistance patterns. Testing for the erm(41) gene, which confers inducible macrolide resistance, is often a key eligibility criterion or stratification factor in trials testing macrolide-containing treatment regimens. Knowing whether a patient’s bacterial strain has this resistance mechanism helps researchers interpret trial results more accurately.^[4][11]

Some trials also use advanced techniques to measure the amount of bacteria present in samples, which allows for more precise monitoring of treatment response. These quantitative measures can detect small changes in bacterial loads that might not be apparent with standard culture methods alone, providing earlier signals about whether a treatment is working.^[10]

Clinical Assessments and Quality of Life Measures

Beyond laboratory and imaging tests, clinical trials typically assess patients’ symptoms and quality of life using standardized questionnaires. These assessments help researchers understand whether new treatments not only clear bacteria but also improve how patients feel and function in daily life. Common symptoms monitored include cough frequency and severity, sputum production, shortness of breath, fatigue, and weight changes.^[12]

Researchers also track indicators of overall health status such as body mass index (BMI), which has been identified as an important prognostic factor in Mycobacterium abscessus infection. Low BMI at diagnosis has been associated with progressive disease and poorer outcomes, so trials often monitor weight changes throughout treatment.^[16]

Specialized Laboratory Testing

Some clinical trials investigating new therapies conduct specialized testing that goes beyond routine diagnostics. For example, trials may test bacterial samples for their susceptibility to experimental drugs or drug combinations that are not yet standard treatments. This testing helps identify which patients are most likely to benefit from the investigational therapy and provides valuable information about the drug’s activity against different bacterial strains.^[10]

Advanced trials may also include research into bacterial genetics and molecular mechanisms of resistance. By studying samples from trial participants, researchers can better understand how Mycobacterium abscessus develops resistance to treatments and potentially identify new drug targets for future therapies. This type of testing contributes to the broader scientific understanding of the infection even if it is not directly used for patient care decisions.^[10]